LegisTrack
Back to all bills
SRES 270119th CongressIntroduced

A resolution designating June 6, 2025, as National Naloxone Awareness Day.

Introduced: Jun 10, 2025
Healthcare
Standard Summary
Comprehensive overview in 1-2 paragraphs

This is a non-binding Senate resolution designating June 6, 2025, as National Naloxone Awareness Day. It highlights the ongoing opioid epidemic and the role of naloxone—an emergency medication that can reverse opioid overdoses and save lives—in reducing fatalities and preventing brain injury. The resolution emphasizes education for the public, families, healthcare professionals, and first responders on naloxone’s benefits and how to administer it, and it identifies barriers to access (notably cost). It urges federal, state, local governments, and private/nonprofit organizations to work together to expand naloxone access and education. It also directs several federal agencies to continue supporting public awareness, harm reduction, and overdose prevention as part of the national drug strategy.

Key Points

  • 1Designates June 6, 2025, as National Naloxone Awareness Day.
  • 2Asserts naloxone is a safe, effective, life-saving medication that can reverse opioid overdoses and reduce fatalities and potential long-term brain injury; notes the CDC views it as a key tool in preventing overdose deaths.
  • 3Stresses the need to educate individuals and communities about naloxone’s benefits and safe administration, and to identify and address barriers to access (including cost).
  • 4Calls for collaboration among federal, state, local governments, private sector, and nonprofit organizations to expand access, education, and distribution of naloxone.
  • 5Urges relevant federal agencies (e.g., SAMHSA, CDC, ONDCP, DEA) and others involved in the National Drug Control Strategy to continue promoting public awareness, harm reduction, and overdose/poisoning prevention.

Impact Areas

Primary group/area affected: Individuals at risk of opioid overdose, bystanders, families, healthcare professionals, and first responders who may administer naloxone.Secondary group/area affected: Federal, state, and local governments; pharmacists, clinics, and harm-reduction programs; private and nonprofit organizations involved in overdose prevention and naloxone distribution.Additional impacts: Potential reduction in overdose fatalities and brain injury through increased bystander intervention and access to naloxone; stigma reduction related to substance use disorders; may influence future policy discussions and resource allocation for naloxone access and education.
Generated by gpt-5-nano on Oct 3, 2025